BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...$105 million series B raise that tripled its reserves.Australia’s Clarity Pharmaceuticals Pty. Ltd. and Germany’s PentixaPharm GmbH...
...markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium Pharmaceuticals Inc. Nordic Nanovector ASA Clarity Pharmaceuticals Pty. Ltd. PentixaPharm GmbH radiotherapy radiotherapies radiopharmaceuticals targeted...
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...With its €15 million ($16.5 million) series A led by ELSA Eckert Life Science Accelerator, PentixaPharm GmbH...
...4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm GmbH...
Items per page:
1 - 2 of 2
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...$105 million series B raise that tripled its reserves.Australia’s Clarity Pharmaceuticals Pty. Ltd. and Germany’s PentixaPharm GmbH...
...markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium Pharmaceuticals Inc. Nordic Nanovector ASA Clarity Pharmaceuticals Pty. Ltd. PentixaPharm GmbH radiotherapy radiotherapies radiopharmaceuticals targeted...
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...With its €15 million ($16.5 million) series A led by ELSA Eckert Life Science Accelerator, PentixaPharm GmbH...
...4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm GmbH...
Items per page:
1 - 2 of 2